BioWa Announces License of POTELLIGENT(R) Technology to Agensys

PRINCETON, New Jersey, November 15, 2010 - BioWa, Inc. announced today that it has entered into a license agreement
with Agensys, Inc., an affiliate of Tokyo based Astellas Pharma Inc.,
providing Agensys with access to BioWa's POTELLIGENT(R) Technology platform
for the purpose of identifying antibodies with enhanced antibody-dependent
cellular cytotoxicity (ADCC).

"We are extremely pleased about our Agreement with Agensys, a leading
monoclonal antibody organization with a focus on therapies against solid
tumors," commented Dr. Masamichi Koike, BioWa's President and CEO. "Agensys
world-class R&D organization and breath of targets in solid tumors will
greatly extend the benefits of the POTELLIGENT(R) Technology."

Under the terms of the license agreement, BioWa grants Agensys
non-exclusive rights to conduct research activities using POTELLIGENT(R)
Technology for an undisclosed number of targets. In return, BioWa will
receive annual research license fees. Other details of the agreement are not
disclosed.

About POTELLIGENT(R) Technology

POTELLIGENT(R) Technology improves potency and efficacy of antibody
therapeutics, by enhancing ADCC, one of the major mechanisms of action for
antibody therapeutics. POTELLIGENT(R) Technology involves the reduction of
the amount of fucose in the carbohydrate structure of an antibody using a
proprietary fucosyltransferase-knockout Chinese Hamster Ovary (CHO) cell line
as a production cell. Research shows that POTELLIGENT(R) Technology
dramatically enhances ADCC activity of an antibody in vitro, and
significantly increases potency and efficacy of the antibody in vivo. A
number of POTELLIGENT(R) antibodies are being investigated in human clinical
trials.

About BioWa, Inc.

BioWa is a wholly owned subsidiary of Kyowa Hakko Kirin Co., Ltd.,
Japan's leading pharmaceutical and largest biotech company, and is the
exclusive worldwide licensor for the AccretaMab(R) platform. The
AccretaMab(R) platform consists of POTELLIGENT(R) and COMPLEGENT(R)
Technologies, creating superior antibody molecules with enhanced ADCC and CDC
activities. BioWa is offering POTELLIGENT(R) and COMPLEGENT(R) Technologies
to partners under a license to maximize the value of these technologies.
Together with Kyowa Hakko Kirin, BioWa is committed to promote ADCC/CDC
enhanced monoclonal antibody-based therapeutics to fight cancer and other
life-threatening and debilitating diseases. For more information about BioWa,
visit its web site at www.biowa.com.

POTELLIGENT(R), COMPLEGENT(R), and AccretaMab(R) are the trademarks of
Kyowa Hakko Kirin Co., Ltd. All rights are reserved.

About Agensys

Agensys, Inc., an affiliate of Astellas Pharma Inc., is developing a
pipeline of fully human monoclonal antibodies (mAbs) to treat cancer. The mAb
product pipeline is being generated to Agensys' diverse portfolio of
proprietary, clinically relevant cancer targets. The company has full
capabilities to generate, develop and manufacture antibody products. Agensys
is progressing a pipeline of both naked and antibody-drug conjugated (ADC)
therapeutic antibodies.

Masamichi Koike, Ph.D., President and CEO, BioWa, Inc., +1-609-580-7500